Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,673 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06. Following the completion of the sale, the insider now owns 124,207 shares of the company’s stock, valued at $1,020,981.54. This trade represents a 9.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Candel Therapeutics Price Performance

CADL opened at $8.18 on Friday. The business has a fifty day moving average of $6.37 and a 200 day moving average of $6.22. The stock has a market cap of $265.65 million, a P/E ratio of -4.73 and a beta of -1.20. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66. Candel Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $14.60.

Institutional Trading of Candel Therapeutics

A number of large investors have recently made changes to their positions in the stock. FMR LLC purchased a new stake in Candel Therapeutics in the 3rd quarter valued at about $46,000. Geode Capital Management LLC boosted its holdings in shares of Candel Therapeutics by 12.8% in the third quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after purchasing an additional 51,111 shares during the period. Barclays PLC grew its stake in Candel Therapeutics by 327.1% in the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after purchasing an additional 21,971 shares in the last quarter. State Street Corp raised its position in Candel Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after purchasing an additional 19,207 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Candel Therapeutics in the 2nd quarter worth $162,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $19.00 price objective (up previously from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.